ALRN Insider Trading

90.89% of Aileron Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Aileron Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/8/2024	Texas Capital Bank Wealth Management Services Inc	15,773	$48K	0.0%	N/A	0.323%
2/1/2024	Sigma Planning Corp	16,580	$51K	0.0%	N/A	0.339%
2/15/2023	Alerce Investment Management L.P.	830,466	$1.97M	2.3%	-95.0%	18.288%
2/10/2023	Blair William & Co. IL	67,867	$0.16M	0.0%	-94.5%	1.495%
1/31/2023	KCK LTD.	22,341	$53K	0.1%	-95.0%	0.492%
10/31/2022	KCK LTD.	446,817	$0.10M	0.2%	-30.9%	0.492%
4/25/2022	Bailard Inc.	128,010	$66K	0.0%	N/A	0.141%
2/14/2022	Blair William & Co. IL	1,067,489	$0.60M	0.0%	+32.9%	1.179%
2/11/2022	KCK LTD.	646,817	$0.36M	0.3%	N/A	0.714%
2/10/2022	Acadian Asset Management LLC	85,274	$47K	0.0%	N/A	0.094%
2/4/2022	Envestnet Asset Management Inc.	136,760	$77K	0.0%	+152.4%	0.151%
2/2/2022	PVG Asset Management Corp	50,300	$28K	0.1%	+113.5%	0.056%
1/27/2022	Morgan Jess S & Co. Inc.	100,000	$56K	0.0%	+33.3%	0.110%
11/16/2021	Keebeck Wealth Management LLC	76,000	$78K	0.0%	-51.2%	0.084%
11/12/2021	Renaissance Technologies LLC	734,721	$0.75M	0.0%	-28.7%	0.811%
11/9/2021	Morgan Jess S & Co. Inc.	75,000	$76K	0.1%	N/A	0.083%
11/9/2021	Barclays PLC	25,279	$26K	0.0%	+235.4%	0.028%
11/9/2021	JFS Wealth Advisors LLC	31,807	$32K	0.0%	N/A	0.035%
10/26/2021	Game Plan Financial Advisors LLC	127,000	$0.13M	0.1%	+27.0%	0.140%
8/17/2021	Boothbay Fund Management LLC	393,015	$0.49M	0.0%	+11.8%	0.434%
8/16/2021	State Street Corp	71,200	$89K	0.0%	N/A	0.079%
8/13/2021	Renaissance Technologies LLC	1,031,128	$1.29M	0.0%	-17.5%	1.142%
8/13/2021	Geode Capital Management LLC	766,813	$0.96M	0.0%	+34.1%	0.849%
8/13/2021	Vanguard Group Inc.	3,440,633	$4.30M	0.0%	-5.9%	3.809%
8/12/2021	Blair William & Co. IL	688,044	$0.86M	0.0%	+99.1%	0.762%
8/4/2021	Envestnet Asset Management Inc.	34,654	$43K	0.0%	+45.1%	0.038%
5/21/2021	Citadel Advisors LLC	46,830	$67K	0.0%	N/A	0.052%
5/19/2021	Virtu Financial LLC	146,341	$0.21M	0.0%	+746.6%	0.162%
5/18/2021	BVF Inc. IL	5,265,555	$7.53M	0.3%	N/A	5.829%
5/18/2021	Citadel Advisors LLC	46,830	$67K	0.0%	N/A	0.052%
5/17/2021	Ikarian Capital LLC	2,800,000	$4M	0.1%	N/A	3.100%
5/13/2021	Renaissance Technologies LLC	1,250,500	$1.79M	0.0%	+97.1%	1.385%
5/13/2021	Blair William & Co. IL	345,594	$0.49M	0.0%	+29.0%	0.383%
5/12/2021	Northern Trust Corp	127,883	$0.18M	0.0%	+378.0%	0.142%
5/12/2021	Geode Capital Management LLC	571,738	$0.82M	0.0%	+149.3%	0.633%
5/12/2021	Satter Management CO. L.P.	16,609,449	$23.75M	10.5%	+118.3%	18.394%
5/11/2021	Acadian Asset Management LLC	134,419	$0.19M	0.0%	+30.8%	0.149%
5/5/2021	Wade G W & Inc.	100,993	$0.14M	0.0%	N/A	0.112%
5/4/2021	Envestnet Asset Management Inc.	23,886	$34K	0.0%	+105.2%	0.026%
4/28/2021	Game Plan Financial Advisors LLC	77,500	$0.11M	0.1%	+13.1%	0.086%
2/11/2021	Satter Management CO. L.P.	7,609,449	$7.91M	3.1%	N/A	9.101%
2/10/2021	Renaissance Technologies LLC	634,381	$0.66M	0.0%	-47.3%	0.759%
2/9/2021	Blair William & Co. IL	267,994	$0.28M	0.0%	+10.8%	0.321%
2/4/2021	GSA Capital Partners LLP	86,562	$90K	0.0%	N/A	0.198%
1/20/2021	Kestra Advisory Services LLC	30,000	$33K	0.0%	N/A	0.068%
1/19/2021	Game Plan Financial Advisors LLC	68,500	$71K	0.1%	N/A	0.156%
11/9/2020	Acadian Asset Management LLC	40,704	$53K	0.0%	N/A	0.102%
10/20/2020	Wedbush Securities Inc.	35,000	$45K	0.0%	N/A	0.088%
8/12/2020	Goldman Sachs Group Inc.	24,971	$29K	0.0%	N/A	0.064%
8/12/2020	Blair William & Co. IL	238,544	$0.28M	0.0%	-21.5%	0.608%
8/7/2020	Virtu Financial LLC	23,309	$28K	0.0%	N/A	0.061%
8/3/2020	Personal CFO Solutions LLC	47,388	$56K	0.0%	+106.0%	0.124%
5/11/2020	Blair William & Co. IL	303,944	$0.10M	0.0%	-12.7%	1.072%
2/20/2020	Geode Capital Management LLC	91,895	$52K	0.0%	+67.1%	0.330%

Data available starting January 2016

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $4.75

$4.51

$4.99

50 Day Range

MA: $5.40

$4.25

$7.09

52 Week Range

Now: $4.75

$1.01

$7.42

Volume

67,714 shs

Average Volume

138,283 shs

Market Capitalization

$80.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.22

Who are the company insiders with the largest holdings of Aileron Therapeutics?: Aileron Therapeutics' top insider shareholders include:
James Brian Windsor (COO)
Learn More about top insider investors at Aileron Therapeutics.